The survival curves showed that EGFR ECD mutations may have a predictive negative role in patients treated with panitumumab, but considering the worst survival of ICC patients having EGFR ECD mutations as compared to WT, the impact of EGFR ECD mutations may be rather prognostic, at least in this site subgroup. The gene discussed is EGFR; the disease is intrahepatic cholangiocarcinoma.